These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35225932)

  • 1. Evaluation of Two Methods for Quantification of Glycosaminoglycan Biomarkers in Newborn Dried Blood Spots from Patients with Severe and Attenuated Mucopolysaccharidosis Type II.
    Herbst ZM; Urdaneta L; Klein T; Burton BK; Basheeruddin K; Liao HC; Fuller M; Gelb MH
    Int J Neonatal Screen; 2022 Jan; 8(1):. PubMed ID: 35225932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Multiple Methods for Quantification of Glycosaminoglycan Biomarkers in Newborn Dried Blood Spots from Patients with Severe and Attenuated Mucopolysaccharidosis-I.
    Herbst ZM; Urdaneta L; Klein T; Fuller M; Gelb MH
    Int J Neonatal Screen; 2020 Sep; 6(3):69. PubMed ID: 33123640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous, non-reducing end glycosaminoglycan biomarkers are superior to internal disaccharide glycosaminoglycan biomarkers for newborn screening of mucopolysaccharidoses and GM1 gangliosidosis.
    Herbst ZM; Hong X; Urdaneta L; Klein T; Waggoner C; Liao HC; Kubaski F; Giugliani R; Fuller M; Gelb MH
    Mol Genet Metab; 2023; 140(1-2):107632. PubMed ID: 37407323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan.
    Chuang CK; Lin HY; Wang TJ; Huang YH; Chan MJ; Liao HC; Lo YT; Wang LY; Tu RY; Fang YY; Chen TL; Ho HC; Chiang CC; Lin SP
    Orphanet J Rare Dis; 2018 May; 13(1):84. PubMed ID: 29801497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report of Five Years of Experience in Neonatal Screening for Mucopolysaccharidosis Type I and Review of the Literature.
    Gragnaniello V; Gueraldi D; Rubert L; Manzoni F; Cazzorla C; Giuliani A; Polo G; Salviati L; Burlina A
    Int J Neonatal Screen; 2020 Nov; 6(4):. PubMed ID: 33147872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combined use of enzyme activity and metabolite assays as a strategy for newborn screening of mucopolysaccharidosis type I.
    Polo G; Gueraldi D; Giuliani A; Rubert L; Cazzorla C; Salviati L; Marzollo A; Biffi A; Burlina AP; Burlina AB
    Clin Chem Lab Med; 2020 Nov; 58(12):2063-2072. PubMed ID: 32432561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.
    de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N
    Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newborn screening for mucopolysaccharidoses: Measurement of glycosaminoglycans by LC-MS/MS.
    Stapleton M; Kubaski F; Mason RW; Shintaku H; Kobayashi H; Yamaguchi S; Taketani T; Suzuki Y; Orii K; Orii T; Fukao T; Tomatsu S
    Mol Genet Metab Rep; 2020 Mar; 22():100563. PubMed ID: 31956510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of iduronate-2-sulfatase gene variants detected in newborn screening for mucopolysaccharidosis type II in Japan.
    Hattori Y; Sawada T; Kido J; Sugawara K; Yoshida S; Matsumoto S; Inoue T; Hirose S; Nakamura K
    Mol Genet Metab Rep; 2023 Dec; 37():101003. PubMed ID: 38053932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The North Carolina Experience with Mucopolysaccharidosis Type I Newborn Screening.
    Taylor JL; Clinard K; Powell CM; Rehder C; Young SP; Bali D; Beckloff SE; Gehtland LM; Kemper AR; Lee S; Millington D; Patel HS; Shone SM; Woodell C; Zimmerman SJ; Bailey DB; Muenzer J
    J Pediatr; 2019 Aug; 211():193-200.e2. PubMed ID: 31133280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rapid and non-invasive proteomic analysis using DBS and buccal swab for multiplexed second-tier screening of Pompe disease and Mucopolysaccharidosis type I.
    Zhang T; Duong P; Dayuha R; Collins CJ; Beckman E; Thies J; Chang I; Lam C; Sun A; Scott AI; Thompson J; Singh A; Khaledi H; Gelb MH; Hahn SH
    Mol Genet Metab; 2022 Aug; 136(4):296-305. PubMed ID: 35787971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dried blood spots allow targeted screening to diagnose mucopolysaccharidosis and mucolipidosis.
    Cobos PN; Steglich C; Santer R; Lukacs Z; Gal A
    JIMD Rep; 2015; 15():123-32. PubMed ID: 24798265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newborn Screening Program for Mucopolysaccharidosis Type II and Long-Term Follow-Up of the Screen-Positive Subjects in Taiwan.
    Lin HY; Chang YH; Lee CL; Tu YR; Lo YT; Hung PW; Niu DM; Liu MY; Liu HY; Chen HJ; Kao SM; Wang LY; Ho HJ; Chuang CK; Lin SP
    J Pers Med; 2022 Jun; 12(7):. PubMed ID: 35887520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples.
    Dean CJ; Bockmann MR; Hopwood JJ; Brooks DA; Meikle PJ
    Clin Chem; 2006 Apr; 52(4):643-9. PubMed ID: 16497940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I.
    Peck DS; Lacey JM; White AL; Pino G; Studinski AL; Fisher R; Ahmad A; Spencer L; Viall S; Shallow N; Siemon A; Hamm JA; Murray BK; Jones KL; Gavrilov D; Oglesbee D; Raymond K; Matern D; Rinaldo P; Tortorelli S
    Int J Neonatal Screen; 2020 Mar; 6(1):10. PubMed ID: 33073008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a newborn screening tool for mucopolysaccharidosis type I based on bivariate normal limits: Using glycosaminoglycan and alpha-L-iduronidase determinations on dried blood spots to predict symptoms.
    Langan TJ; Jalal K; Barczykowski AL; Carter RL; Stapleton M; Orii K; Fukao T; Kobayashi H; Yamaguchi S; Tomatsu S
    JIMD Rep; 2020 Mar; 52(1):35-42. PubMed ID: 32154058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newborn Screening for Mucopolysaccharidoses: Results of a Pilot Study with 100 000 Dried Blood Spots.
    Scott CR; Elliott S; Hong X; Huang JY; Kumar AB; Yi F; Pendem N; Chennamaneni NK; Gelb MH
    J Pediatr; 2020 Jan; 216():204-207. PubMed ID: 31732130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digital Microfluidics in Newborn Screening for Mucopolysaccharidoses: A Progress Report.
    Washburn J; Millington DS
    Int J Neonatal Screen; 2020 Oct; 6(4):. PubMed ID: 33124616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice.
    Shimada Y; Wakabayashi T; Akiyama K; Hoshina H; Higuchi T; Kobayashi H; Eto Y; Ida H; Ohashi T
    Mol Genet Metab; 2016 Feb; 117(2):140-3. PubMed ID: 26051019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.